Changes in endogenous tissue glutathione level in relation to murine ascites tumor growth and the anticancer activity of cisplatin

Brazilian Journal of Medical and Biological Research

Volumn 36, Issue 1, 2003, Pages 53-63

  Khynriam, D ^a   Prasad, S B ^a  

^a NORTH EASTERN HILL UNIVERSITY   (India)

Author keywords

Chemotherapy; Cisplatin; Dalton's lymphoma; Glutathione; Glutathione S transferase

Indexed keywords

BUTHIONINE SULFOXIMINE; CISPLATIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; BLOOD ANALYSIS; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG UPTAKE; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; IN VIVO STUDY; INHIBITION KINETICS; KIDNEY DISEASE; KIDNEY PARENCHYMA; LOW DRUG DOSE; LYMPHOMA; LYMPHOMA CELL; MOUSE; MOUSE STRAIN; MUTAGENESIS; NONHUMAN; SPLEEN; SPLEEN CELL; TESTIS; TIME; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALIA; MURINAE;

EID: 0037283401     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2003000100008     Document Type: Article

References (40)

1. Rosenberg B (1985). Fundamental studies with cisplatin. Cancer, 55: 2303-2316.
2. Prasad SB & Giri A (1994). Antitumour effect of cisplatin against murine ascites Dalton's lymphoma. Indian Journal of Experimental Biology, 32: 155-162.
3. Go RS & Adjei AA (1999). Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. Journal of Clinical Oncology, 17: 409-422.
4. Chu G (1994). Cellular responses to cisplatin. Journal of Biological Chemistry, 269: 787-790.
5. Collins JL & Kao M (1989). The anticancer drug cisplatin increases the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunology, Immunotherapy, 29: 17-22.
6. Prasad SB & Sodhi A (1981). Effect of cis-dichlorodiammineplatinum (II) on the agglutinability of tumor and normal cells with concanavalin A and wheat germ agglutinin. Chemico-Biological Interactions, 36: 355-367.
7. Prasad SB & Giri A (1999). Cisplatin-induced changes in tissue calcium and potassium concentrations in tumour-bearing mice. Medical Science Research, 27: 459-462.
8. Prasad SB, Giri A, Khynriam D, Kharbangar A, Nicol BM & Lotha C (1999). Cisplatin-mediated enzymatic changes in mice bearing ascites Dalton's lymphoma. Medical Science Research, 27: 723-730.
9. Kharbangar A, Khynriam D & Prasad SB (2000). Effect of cisplatin on mitochondrial protein, glutathione, and succinate dehydrogenase in Dalton lymphoma-bearing mice. Cell Biology and Toxicology, 16: 363-373.
10. Krakoff IH (1979). Nephrotoxicity of cis-dichlorodiammineplatinum. Cancer Treatment Reports, 63: 1523-1525.
11. Khynriam D & Prasad SB (2001). Hematotoxicity and blood glutathione levels after cisplatin treatment of tumor-bearing mice. Cell Biology and Toxicology, 17: 357-370.
12. Giri A, Khynriam D & Prasad SB (1998). Vitamin C mediated protection on cisplatin-induced mutagenicity in mice. Mutation Research, 421: 139-148.
13. Prasad SB & Khynriam D (2002). Mutagenicity and endogenous glutathione levels in tumor-bearing mice after cisplatin treatment. In: Khassanova L, Collery P, Maymard I, Khassanova Z & Etienne JC (Editors), Metal Ions in Biology and Medicine. Vol. 7. John Libbey Eurotext, Paris, France, 580-585.
14. Kartalou M & Essigmann JM (2001). Mechanisms of resistance to cisplatin. Mutation Research, 478: 23-48.
15. Giri A, Khynriam D & Prasad SB (1998). Use of vitamin C against cisplatin induced mutagenicity and nephrotoxicity. In: Sharan RN (Editor), Trends in Radiation and Cancer Biology. Forschungszentrum Jülich GmbH, Jülich, Germany, 166-176.
16. Bailey HH (1998). L-S,R-buthionine sulfoximine: historical development and clinical issues. Chemico-Biological Interactions, 111-112: 239-254.
17. Prasad SB, Khokhar AR & Siddik ZH (1994). Potentiation by L-buthionine sulfoximine (BSO) of cytotoxicity of platinum(IV) complexes in sensitive and resistant human ovarian carcinoma cells. In: Collery P, Poirier LA, Littlefield NA & Etienne JC (Editors), Metal Ions in Biology and Medicine. Vol. 3. John Libbey Eurotext, Paris, France, 365-370.
18. Arrick BA & Nathan CF (1984). Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Research, 44: 4224-4232.
19. Wang W & Ballatori N (1998). Endogenous glutathione conjugates: occurrence and biological functions. Pharmacological Reviews, 50: 335-355.
20. Suzuki CAM & Cherian MG (1990). The interaction of cis-diamminedichloroplatinum with metallothionein and glutathione in rat liver and kidney. Toxicology, 64: 113-127.
21. Beutler E, Dunn O & Kelly BM (1963). Improved method for the determination of blood glutathione. Journal of Laboratory and Clinical Medicine, 65: 882-888.
22. Sedlak J & Lindsay RH (1968). Estimation of total, protein-bound and nonprotein sulfhydryl groups in tissues with Ellman's reagent. Analytical Biochemistry, 25: 192-205.
23. Habig WH, Pabot MJ & Jarkoby WB (1974). Glutathione-S-transferase. The first enzymatic step in mercapturic acid formation. Journal of Biological Chemistry, 249: 7130-7139.
24. Lowry OH, Rosebrough NJ, Farr AL & Randall RJ (1951). Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193: 265-275.
25. Dileepan KN, Lorsbach RB & Stechschutte DJ (1993). Mast cell granules inhibit macrophage-mediated lysis of mastocytoma cells (P815) and nitric oxide production. Journal of Leukocyte Biology, 53: 446-453.
26. Estrela JM, Sternandez R, Terradez P, Asensi M, Puertes IR & Vina J (1992). Regulation of glutathione metabolism in Ehrlich ascites tumour cells. Biochemical Journal, 286: 257-262.
27. Szatrowski TP & Nathan CF (1991). Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Research, 51: 794-798.
28. Toyokuni S, Okamoto K, Yodoi J & Hiai H (1995). Persistent oxidative stress in cancer. FEBS Letters, 358: 1-3.
29. Estrela JM, Obrador E, Navarro J, Lasso De La Vega MC & Pellicer JA (1995). Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Nature Medicine, 1: 84-88.
30. Shaw JP & Chou IN (1986). Elevation of intracellular glutathione content associated with mitogenic stimulation of quiescent fibroblasts. Journal of Cellular Physiology, 129: 193-198.
31. Terradez P, Asensi M, Lasso De La Vega MC, Puertes IR, Vina J & Estrela JM (1993). Depletion of tumour glutathione in vivo by buthionine sulfoximine: modulation by the rate of cellular proliferation and inhibition of cancer growth. Biochemical Journal, 292: 477-483.
32. Amores-Sanchez MI & Medina MA (1999). Glutamine as a precursor of glutathione and oxidative stress. Molecular Genetics and Metabolism, 67: 100-105.
33. Hinchman CA & Ballotori N (1994). Glutathione conjugation and conversion to mercapturic acid can occur as an intrahepatic process. Journal of Toxicology and Environmental Health, 41: 387-409.
34. DellaRovere F, Granata A, Saija A, Broccio, M, Tomaino A, Zirilli A, De Caridi G & Broccio, G (2000). -SH groups and glutathione in cancer patient's blood. Anticancer Research, 20: 1595-1598.
35. Welters MJP, Fichtinger-Schepman AMJ, Baan RA, Flens MJ, Scheper RJ & Braakhuis BJM (1998). Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines. British Journal of Cancer, 77: 556-561.
36. Ishikawa T & Ali-Osman F (1993). Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells: molecular characterization of glutathione platinum complex and its biological significance. Journal of Biological Chemistry, 268: 20116-20125.
37. Hansson J, Berhane K, Castro VM, Jungnelius U, Mannervik B & Ringborg U (1991). Sensitization to human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor, ethacrynic acid. Cancer Research, 51: 94-98.
38. Canada AT, Herman L, Kidd K, Robertson C & Trump D (1993). Glutathione depletion increases the cytotoxicity of melphalan to the androgen-sensitive prostate cancer cell line, PC-3. Cancer Chemotherapy and Pharmacology, 32: 73-77.
39. Prasad SB, Giri A & Arjun J (1992). Use of subtherapeutical dose of cisplatin and vitamin C against murine ascites Dalton's lymphoma. Polish Journal of Pharmacology and Pharmacy, 44: 383-391.
40. Szymkowski DE, Yarema K, Essigmann JM, Lippard SJ & Wood RD (1992). An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proceedings of the National Academy of Sciences, USA, 89: 10772-10776.